Kelly N Godby MD

Associate Professor, Medicine, University of Alabama School of Medicine

619 19th St SBirmingham, AL 35249
Phone+1 205-934-5038

Dr. Godby is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Godby's full profile Already have an account?

Education & Training

University of Alabama Hospital (Birmingham)Fellowship, Hematology and Medical Oncology, 2008 - 2011
University of Alabama Hospital (Birmingham)Residency, Internal Medicine, 2005 - 2008
Mercer University School of MedicineClass of 2005

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

AL State Medical License 2007 - 2026
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification HealthSentry, Cerner Corporation, 2012, 2014, 2016-2017
CMS Meaningful Use Stage 2 Certification FairWarning® Patient Privacy Monitoring, FairWarning Technologies, LLC, 2012, 2014, 2016-2017
CMS Meaningful Use Stage 2 Certification Cerner Patient Portal and Powerchart, Cerner Corporation, 2012, 2014, 2016-2017

Clinical Trials

Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy
COMPLETED
PHASE3

Publications & Presentations

PubMed

Measurable residual disease-guided, fixed-duration, potentially definitive therapy for standard risk newly diagnosed multiple myeloma.
Bhagirathbhai R Dholaria, Eva Medvedova, Gayathri Ravi, Binod Dhakal, Natalie S Callander
Leukemia. 2026-10-06
1 citations
Redefining functional high-risk multiple myeloma in the context of upfront quadruplet therapy and autologous stem cell transplantation.
Gayathri Ravi, Binod Dhakal, Natalie S Callander, Eva Medvedova, Bhagirathbhai R Dholaria
Cancer. 2026-07-15
4 citations
Distinct trajectory of measurable residual disease in t(11;14) myeloma treated with quadruplet therapy.
Susan Bal, Gayathri Ravi, Binod Dhakal, Natalie S Callander, Eva Medvedova
Blood. 2026-04-16

Journal Articles

Second Primary Malignancy After Multiple Myeloma‐Population Trends and Cause‐Specific Mortality
Parameswaran Hari, Luciano J Costa, Saurabh Chhabra, Kelly N Godby, British Journal of Haematology

Abstracts/Posters

Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...
Kelly N. Godby, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Di...
Kelly N. Godby, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...
Kelly N. Godby, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures